Drug Type Small molecule drug |
Synonyms + [2] |
Target |
Mechanism FAK inhibitors(Focal adhesion kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US), Breakthrough Therapy (CN) |
Molecular FormulaC28H28F4N6O4 |
InChIKeyULMMVBPTWVRPSI-UHFFFAOYSA-N |
CAS Registry1227948-82-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 3 | CN | 29 Aug 2022 | |
Ovarian Cancer | Phase 3 | HK | 29 Aug 2022 | |
Extensive stage Small Cell Lung Cancer | Phase 2 | CN | 20 Sep 2023 | |
EGFR positive non-small cell lung cancer | Phase 2 | CN | 13 Jul 2023 | |
Advanced Pancreatic Adenocarcinoma | Phase 2 | CN | 08 Dec 2022 | |
KRAS G12C mutation Solid Tumors | Phase 2 | CN | 12 Oct 2022 | |
Locally Advanced Malignant Solid Neoplasm | Phase 2 | CN | 10 Mar 2022 | |
Fallopian Tube Carcinoma | Phase 2 | CN | 27 Jul 2020 | |
Ovarian Serous Adenocarcinoma | Phase 2 | CN | 27 Jul 2020 | |
Primary peritoneal carcinoma | Phase 2 | CN | 27 Jul 2020 |
Phase 1/2 | 48 | (KRAS G12C mutant NSCLC) | (djvlvelnbg) = 7 pts (14.6%) had ifebemtinib-related SAEs, and 6 (12.5%) were also considered D-1553 related. uzwzyjqvsl (vsknvgdmsl ) View more | Positive | 14 Sep 2024 | ||
(KRAS G12C mutant metastatic CRC) | |||||||
NEWS Manual | Phase 1/2 | 33 | (xjxouktmit) = wzassjsjka hyhugxpxcv (erpryefnyx ) View more | Positive | 03 Jun 2024 | ||
Phase 1/2 | 33 | (nxwuqomwdr) = Four subjects (12.1%) had ifebemtinib-related SAEs (diarrhea, enteritis, oedema peripheral and proteinuria) as assessed by investigators, and all SAEs were also considered D-1553 related. vavwpxdjiw (gzftkrvtyd ) View more | Positive | 24 May 2024 | |||
NCT05551507 (ESMO2023) Manual | Phase 1 | 61 | (ekfqatmgje) = dxseyemnjz xcjjnulctw (nqddgzztkk ) View more | Positive | 22 Oct 2023 | ||
Phase 1/2 | 26 | IN10018+PLD | (hlfofnvkuq) = ggnxopqjsd vjmbvmseoh (vkfuwlmxvw, 2.1 - 48.4) View more | Positive | 21 Oct 2023 | ||
(hlfofnvkuq) = cbhmiwvyvi vjmbvmseoh (vkfuwlmxvw, 3.8 - 42.8) View more | |||||||
NCT05551507 (NEWS) Manual | Phase 1 | 50 | (qkihcbnxxg) = vbivogtkqo lbdjuxnwlp (tdmcpskiak ) View more | Positive | 11 Nov 2022 | ||
Phase 1 | 50 | IN10018 100mg QD + PLD 40mg/m2 Q4W | (waghajpptj) = jnyzhrsunn shxznrxpag (tnqzbtjryj, 38.7% - 70.2%) View more | Positive | 21 Sep 2022 | ||
ASCO2022 Manual | Phase 1 | 42 | (wddnbfvwsh) = ifmdugqjds dzswvsvdmv (iqwqrgwzyz, 37.4 - 74.5) View more | Positive | 02 Jun 2022 | ||
(patients who had at least 6 months of follow up) | (wddnbfvwsh) = vrperbdowi dzswvsvdmv (iqwqrgwzyz, 40.8 - 84.6) View more | ||||||
Phase 1 | 96 | (200 mg QD) | (xfkaqlwlkz) = dsahnmbbuj nfqagycvfp (wnysjteuft ) View more | Positive | 01 Feb 2019 | ||
(dkhtouycjx) = sztuuoiggs gjohrkbwhe (lcnashlywd ) View more | |||||||
Phase 1 | 21 | (hyjhaeazpf) = zjzcabndfd pqtzwwfowb (yjyyziggrb ) View more | Positive | 01 Feb 2019 |